Corporate digest

Lonza Group

CHEMICALS and biotech company Lonza Group will buy a sterile drug product fill-and-finish facility in Stein, Switzerland, from Novartis. Lonza, which has a secondary listing on the Singapore Exchange, said it had entered into a binding contractual commitment for the acquisition, but did not disclose the purchase price.

It will use the facility to manufacture drug products for Novartis, as well as to provide production capacity for its additional customers.